Skip to main content

Cormorant Asset Management — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

209
Companies
$30.0B
Total invested
$143.6M
Avg. check
14
Industries
Biotechnology 22Health Care 16Therapeutics 12Medical 11Pharmaceutical 8Life Science 6+8 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 209
Dren Bio
October 2026

Dren Bio focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents.

Biotechnology · San Carlos$350.0M Venture - Series Unknown
Aclaris Therapeutics
October 2026

Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.

Biotechnology · Wayne$50.0M Post-IPO Equity
Epicrispr Biotechnologies
October 2026

Epicrispr Biotechnologies is a biotechnology enterprise that focuses on epigenetic engineering.

Biotechnology · South San Francisco$8.0M Grant
Orbis Medicines
September 2026

Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.

Health Care · Frederiksberg$93.5M Corporate Round
Tyra Biosciences
September 2026

Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.

Biotechnology · Carlsbad$400.0M Post-IPO Equity
Crystalys Therapeutics
July 2026

Crystalys Therapeutics is a clinical-stage biopharmaceutical company that develops targeted therapies for gout and hyperuricemia.

Biopharma · San Diego$130.0M Series B
Freenome
July 2026

Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.

Biotechnology · South San Francisco$240.0M Post-IPO Equity
Clearside Biomedical
July 2026

Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.

Biotechnology · Alpharetta$3.0M Post-IPO Debt
Erasca
July 2026

Erasca is a developer of oncology drugs intended to provide precision oncology options.

Biotechnology · San Diego$632.5M Post-IPO Equity
Cue Biopharma
July 2026

Cue Biopharma is a developer of a productive platform for the treatment of cancer and autoimmune disease.

Biopharma · Cambridge$50.0M Post-IPO Equity
Fore Biotherapeutics
July 2026

Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.

Biotechnology · Philadelphia$67.4M Series D
Neurogene
July 2026

Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.

Biotechnology · New York$125.0M Post-IPO Equity
MoonLake Immunotherapeutics
June 2026

MoonLake Immunotherapeutics is a clinical-stage biopharmaceuticals company.

Biotechnology · Zug$200.0M Post-IPO Equity
Triveni Bio
June 2026

Triveni Bio is a biotechnology company that develops antibody-based therapeutics for immunological and inflammatory diseases.

Biotechnology · Watertown$65.0M Series C
Enliven Therapeutics
June 2026

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

Biotechnology · Boulder$460.0M Post-IPO Equity
Tango Therapeutics
June 2026

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

Biotechnology · Cambridge$600.0M Post-IPO Equity
Quince Therapeutics
May 2026

Quince Therapeutics is developing treatments for Alzheimer's and other degenerative disorders.

Biotechnology · South San Francisco$115.0M Post-IPO Equity
Artiva Biotherapeutics
May 2026

Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.

Biotechnology · San Diego$300.0M Post-IPO Equity
Pharvaris
May 2026

Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.

Biotechnology · Zug$132.3M Post-IPO Equity
Cabaletta Bio
May 2026

Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.

Biotechnology · Philadelphia$150.0M Post-IPO Equity
Valneva
April 2026

Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.

Biotechnology · Saint-herblain$43.1M Post-IPO Equity
GH Research
April 2026

GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.

Biopharma · Dublin$117.5M Post-IPO Equity
Climb Bio
April 2026

Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.

Biotechnology · Redmond$110.0M Post-IPO Equity
Oruka Therapeutics
April 2026

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Biotechnology · Waltham$700.4M Post-IPO Equity

Where Cormorant Asset Management invests

Biotechnology22
Health Care16
Therapeutics12
Medical11
Pharmaceutical8
Life Science6

About Cormorant Asset Management's portfolio

How many companies has Cormorant Asset Management invested in?▸

Cormorant Asset Management has invested in 209 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Cormorant Asset Management invest in?▸

Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 14 different industry categories.

What is Cormorant Asset Management's largest investment?▸

Among tracked funding rounds, Oruka Therapeutics received $700.4M in a Post-IPO Equity round. Cormorant Asset Management's total known invested capital is $30.0B.

What is the average investment size for Cormorant Asset Management?▸

Cormorant Asset Management's average investment size is $143.6M across its portfolio of 209 companies.

What are Cormorant Asset Management's most recent investments?▸

Recent Cormorant Asset Management portfolio additions include Dren Bio, Aclaris Therapeutics, Epicrispr Biotechnologies, Orbis Medicines, Tyra Biosciences. These companies were founded in 2020 or later.

Reach the founders behind these 209 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →